Evans syndrome overview: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
Autoimmune hemolytic anemia is a condition in which the [[red blood cells]] that normally carry [[oxygen]] and [[carbon dioxide]] are destroyed by an [[autoimmune]] process. Immune thrombocytopenic purpura is a condition in which the [[platelets]] in the [[blood]] are destroyed by an [[autoimmune]] process. Platelets are a component of blood that contribute to the formation of [[blood clot]]s in the body to prevent [[bleeding]]. Patients with Evans syndrome usually appear normal. Physical examination of patients with Evans syndrome is usually remarkable for jaundice, hepatosplenomegaly, and lymphadenopathy. | Autoimmune hemolytic anemia is a condition in which the [[red blood cells]] that normally carry [[oxygen]] and [[carbon dioxide]] are destroyed by an [[autoimmune]] process. Immune thrombocytopenic purpura is a condition in which the [[platelets]] in the [[blood]] are destroyed by an [[autoimmune]] process. Platelets are a component of blood that contribute to the formation of [[blood clot]]s in the body to prevent [[bleeding]]. Patients with Evans syndrome usually appear normal. Physical examination of patients with Evans syndrome is usually remarkable for jaundice, hepatosplenomegaly, and lymphadenopathy. | ||
Laboratory findings consistent with the diagnosis of Evans syndrome include [[anemia]], direct coombs test positive, and antineutrophil antibody positive. Pharmacologic medical therapies for Evans syndrome include prednisone, intravenous immunoglobulin, and rituximab. Surgery is not the firstline treatment option for patients with Evans syndrome. Splenectomy is usually reserved for patients who are unresponsive to treatment. | Laboratory findings consistent with the diagnosis of Evans syndrome include [[anemia]], direct coombs test positive, and antineutrophil antibody positive. Pharmacologic medical therapies for Evans syndrome include prednisone, intravenous immunoglobulin, and rituximab. Surgery is not the firstline treatment option for patients with Evans syndrome. Splenectomy is usually reserved for patients who are unresponsive to treatment. | ||
==Historical Perspective== | ==Historical Perspective== | ||
Evans syndrome was first described by Dr. Robert S. Evans, an American physician, in 1951. | Evans syndrome was first described by Dr. Robert S. Evans, an American physician, in 1951. | ||
==Pathophysiology== | ==Pathophysiology== | ||
The exact pathogenesis of Evans syndrome is not fully understood. It is thought that Evans syndrome is an autoimmune disorder in which autoantibodies are produced against [[red blood cell]]s and [[platelet]]s. On gross pathology, circumscribed mass with microscopic infiltration is a characteristic finding of Evans syndrome. On microscopic histopathological analysis, alternating fibrous and myxoid stroma of low-grade/low malignant potential, and small tumor cells with scanty eosinophilic cytoplasm with a round to oval nuclei and no nucleoli are characteristic findings of Evans syndrome. | The exact pathogenesis of Evans syndrome is not fully understood. It is thought that Evans syndrome is an autoimmune disorder in which autoantibodies are produced against [[red blood cell]]s and [[platelet]]s. On gross pathology, circumscribed mass with microscopic infiltration is a characteristic finding of Evans syndrome. On microscopic histopathological analysis, alternating fibrous and myxoid stroma of low-grade/low malignant potential, and small tumor cells with scanty eosinophilic cytoplasm with a round to oval nuclei and no nucleoli are characteristic findings of Evans syndrome. | ||
==Causes== | ==Causes== | ||
The cause of Evans syndrome has not been identified. | The cause of Evans syndrome has not been identified. | ||
==Differential | |||
==Differential Evans Syndrome from Other Diseases== | |||
Evans syndrome must be differentiated from acquired thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, Kasabach-Merritt syndrome, fibromatosis, fibrosarcoma, myxofibrosarcoma, nodular fasciitis and myxoid neurofibroma. | Evans syndrome must be differentiated from acquired thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, Kasabach-Merritt syndrome, fibromatosis, fibrosarcoma, myxofibrosarcoma, nodular fasciitis and myxoid neurofibroma. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
The incidence of Evan’s Syndrome is not precisely known. Evan’s Syndrome affects male and female equally. Evan’s Syndrome is a rare disease that tends to affect children. | The incidence of Evan’s Syndrome is not precisely known. Evan’s Syndrome affects male and female equally. Evan’s Syndrome is a rare disease that tends to affect children. | ||
==Risk Factors== | |||
==Natural history, Complications and Prognosis== | ==Natural history, Complications and Prognosis== | ||
If left untreated, patients with Evans syndrome have periods of exacerbation. Common complications of Evans syndrome include thrombocytopenia and autoimmune hemolytic anemia | If left untreated, patients with Evans syndrome have periods of exacerbation. Common complications of Evans syndrome include thrombocytopenia and autoimmune hemolytic anemia. | ||
Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good. | |||
==History and Symptoms== | |||
==Diagnosis== | |||
===History and Symptoms=== | |||
Symptoms of Evans syndrome include [[Dyspnea|breathlessness]], [[fatigue]], [[jaundice]], and dark urine. | Symptoms of Evans syndrome include [[Dyspnea|breathlessness]], [[fatigue]], [[jaundice]], and dark urine. | ||
==Physical Examination== | ===Physical Examination=== | ||
Patients with Evans syndrome usually appear normal. Physical examination of patients with Evans syndrome is usually remarkable for jaundice, hepatosplenomegaly, and lymphadenopathy. | Patients with Evans syndrome usually appear normal. Physical examination of patients with Evans syndrome is usually remarkable for jaundice, hepatosplenomegaly, and lymphadenopathy. | ||
==Laboratory Findings== | ===Laboratory Findings=== | ||
Laboratory findings consistent with the diagnosis of Evans syndrome include [[anemia]], direct coombs test positive, and antineutrophil antibody positive. | Laboratory findings consistent with the diagnosis of Evans syndrome include [[anemia]], direct coombs test positive, and antineutrophil antibody positive. | ||
==Medical Therapy== | ==Treatment== | ||
===Medical Therapy=== | |||
Pharmacologic medical therapies for Evans syndrome include prednisone, intravenous immunoglobulin, and rituximab. | Pharmacologic medical therapies for Evans syndrome include prednisone, intravenous immunoglobulin, and rituximab. | ||
==Surgery== | ===Surgery=== | ||
Surgery is not the firstline treatment option for patients with Evans syndrome. Splenectomy is usually reserved for patients who are unresponsive to treatment. | Surgery is not the firstline treatment option for patients with Evans syndrome. Splenectomy is usually reserved for patients who are unresponsive to treatment. | ||
Revision as of 19:02, 15 June 2016
|
Evans syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Evans syndrome overview On the Web |
|
American Roentgen Ray Society Images of Evans syndrome overview |
|
Risk calculators and risk factors for Evans syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Evans' Syndrome is an autoimmune disease in which an individual's antibodies attack their own RBCs as well as their platelets. Its overall pathology is therefore effectively a combination of the two autoimmune induced conditions: autoimmune hemolytic anemia and immune thrombocytopenic purpura. Autoimmune hemolytic anemia is a condition in which the red blood cells that normally carry oxygen and carbon dioxide are destroyed by an autoimmune process. Immune thrombocytopenic purpura is a condition in which the platelets in the blood are destroyed by an autoimmune process. Platelets are a component of blood that contribute to the formation of blood clots in the body to prevent bleeding. Patients with Evans syndrome usually appear normal. Physical examination of patients with Evans syndrome is usually remarkable for jaundice, hepatosplenomegaly, and lymphadenopathy. Laboratory findings consistent with the diagnosis of Evans syndrome include anemia, direct coombs test positive, and antineutrophil antibody positive. Pharmacologic medical therapies for Evans syndrome include prednisone, intravenous immunoglobulin, and rituximab. Surgery is not the firstline treatment option for patients with Evans syndrome. Splenectomy is usually reserved for patients who are unresponsive to treatment.
Historical Perspective
Evans syndrome was first described by Dr. Robert S. Evans, an American physician, in 1951.
Pathophysiology
The exact pathogenesis of Evans syndrome is not fully understood. It is thought that Evans syndrome is an autoimmune disorder in which autoantibodies are produced against red blood cells and platelets. On gross pathology, circumscribed mass with microscopic infiltration is a characteristic finding of Evans syndrome. On microscopic histopathological analysis, alternating fibrous and myxoid stroma of low-grade/low malignant potential, and small tumor cells with scanty eosinophilic cytoplasm with a round to oval nuclei and no nucleoli are characteristic findings of Evans syndrome.
Causes
The cause of Evans syndrome has not been identified.
Differential Evans Syndrome from Other Diseases
Evans syndrome must be differentiated from acquired thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, Kasabach-Merritt syndrome, fibromatosis, fibrosarcoma, myxofibrosarcoma, nodular fasciitis and myxoid neurofibroma.
Epidemiology and Demographics
The incidence of Evan’s Syndrome is not precisely known. Evan’s Syndrome affects male and female equally. Evan’s Syndrome is a rare disease that tends to affect children.
Risk Factors
Natural history, Complications and Prognosis
If left untreated, patients with Evans syndrome have periods of exacerbation. Common complications of Evans syndrome include thrombocytopenia and autoimmune hemolytic anemia. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good.
Diagnosis
History and Symptoms
Symptoms of Evans syndrome include breathlessness, fatigue, jaundice, and dark urine.
Physical Examination
Patients with Evans syndrome usually appear normal. Physical examination of patients with Evans syndrome is usually remarkable for jaundice, hepatosplenomegaly, and lymphadenopathy.
Laboratory Findings
Laboratory findings consistent with the diagnosis of Evans syndrome include anemia, direct coombs test positive, and antineutrophil antibody positive.
Treatment
Medical Therapy
Pharmacologic medical therapies for Evans syndrome include prednisone, intravenous immunoglobulin, and rituximab.
Surgery
Surgery is not the firstline treatment option for patients with Evans syndrome. Splenectomy is usually reserved for patients who are unresponsive to treatment.